Erdafitinib Tackles an Unmet Need in Urothelial Carcinoma

Brittany Lovely
Published: Thursday, Nov 14, 2019
Arlene O. Siefker-Radtke, MD

Arlene O. Siefker-Radtke, MD
As the first targeted therapy in bladder cancer, erdafitinib (Balversa) expands the limited treatment options for the subset of patients with urothelial carcinoma who harbor FGFR3 or FGFR2 genetic alterations. In results from a phase II clinical trial (NCT02365597), erdafitinib demonstrated a robust response rate and was tolerable in a population with a typically poor prognosis, said Arlene O. Siefker-Radtke, MD.
... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Publication Bottom Border
Border Publication